Do Ozempic and Wegovy slow aging? What the new research shows
Semaglutide, the active ingredient in Ozempic and Wegovy, has transformed weight management over the past few years. Now researchers are asking whether the same drug might also slow how quickly the body ages biologically, and a new study offers the first concrete clinical evidence pointing in that direction.
The research was conducted in adults living with HIV. That group was chosen specifically because HIV infection is associated with accelerated biological aging, driven by chronic inflammation, meaning people living with HIV can carry aging markers that look "older" than their actual chronological age would suggest.
The term "biological aging markers" refers to laboratory measures of how old your cells and DNA actually appear, as distinct from the age shown on your birth certificate. Among the most prominent of these measures are epigenetic clocks, tests that track how chemical markers on DNA change as a person ages.
Researchers found that HIV-positive adults taking semaglutide showed slower progression of these biological aging markers compared with those not taking the drug. It is being described as the first clinical evidence, in real human patients rather than lab animals, that the drug may influence human aging.
Scientists say the finding is exciting but still early stage. The study cannot yet fully distinguish whether the slowdown is driven by weight loss itself, the drug's primary intended effect, or by semaglutide's direct effects on metabolism and inflammation independent of weight change.
That distinction matters. If the effect is purely a byproduct of weight loss, that is already a known and expected outcome. But if semaglutide itself, through some independent mechanism, is slowing cellular aging, that would be a far broader finding with implications for how the drug might eventually be used.
Researchers also note the study was conducted in a specific population living with HIV, so the results cannot be directly generalised to the wider population. Chronic inflammation linked to HIV can affect aging markers in ways that may not translate identically to people without the condition.
Experts are clear that the findings should not be read as "Ozempic makes you younger." The drug is currently approved for treating type 2 diabetes and obesity; it is not prescribed to slow aging, and no regulator has approved it for that purpose.
Still, the finding contributes to a growing body of research suggesting that GLP-1 agonist drugs may affect more than just weight and blood sugar, potentially influencing the body's broader inflammatory and metabolic health profile. Scientists say larger, more diverse patient studies will be needed to confirm whether the effect holds up.
For now, the takeaway is that the first concrete evidence of semaglutide's effect on human biological aging has emerged, but it is far too early to treat the drug as an anti-aging therapy, and scientists are waiting on the results of larger clinical trials before drawing firmer conclusions.
Read next
What is cyclosporiasis, the parasite behind the US's 'explosive' diarrhea outbreak?
The parasite Cyclospora cayetanensis is driving a surge of cases across several US states, with Michigan seeing the largest outbreak in its history. Here's how the illness spreads, its symptoms, and how to avoid it.
Who can access testosterone therapy in the US, and how?
Testosterone therapy has become a fast-growing market in the US, but access runs through several different paths. From traditional endocrinology exams to telehealth platforms and gender-affirming care, who can get a prescription depends on diagnosis, insurance, and state law.
What do sweeteners do to gut bacteria? A 39-compound lab study finds answers
A large laboratory study testing 39 sweeteners found many directly alter the growth of gut bacteria. The most striking finding: combining isosteviol with the antidepressant duloxetine reduced beneficial bacteria and overall microbial diversity.
Focal therapy: what a 10-year NHS trial found about prostate cancer treatment
Focal therapy, a less invasive alternative to removing or irradiating the whole prostate, cut the risk of incontinence and erectile dysfunction in a 10-year NHS trial that followed nearly 3,500 men. Here is how the treatment works and who it might suit.
Dementia risk: why where you live may matter as much as how you live
A study of more than 214,000 people has found that the factors driving dementia risk differ significantly from country to country, challenging the idea of a single global prevention checklist. Some risk factors, though, turned out to be strikingly consistent everywhere researchers looked.